The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population-Reference-Cited by-同舟云学术

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population

Published:2016-07-13 Issue:1 Volume:2 Page:
ISSN:2374-4677
Container-title:npj Breast Cancer
language:en
Short-container-title:npj Breast Cancer

Author:

Wilson Timothy R,Yu Jianjun,Lu Xuyang,Spoerke Jill M,Xiao Yuanyuan,O’Brien Carol,Savage Heidi M,Huw Ling-Yuh,Zou Wei,Koeppen Hartmut,Forrest William F,Fridlyand Jane,Fu Ling,Tam Rachel,Schleifman Erica B,Sumiyoshi Teiko,Molinero Luciana,Hampton Garret M,O’Shaughnessy Joyce A,Lackner Mark R

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology

Link

http://www.nature.com/articles/npjbcancer201622.pdf

Reference43 articles.

1. Hammond, M. E. et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28: 2784–2795 (2010).

2. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406: 747–752 (2000).

3. Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98: 10869–10874 (2001).

4. van 't Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530–536 (2002).

5. van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347: 1999–2009 (2002).

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating the Immunogenic Cell Death-Dependent Subtypes and Prognostic Signature of Triple-Negative Breast Cancer;Phenomics;2024-02

2. Dysfunction of ubiquitin protein ligase MYCBP2 leads to cell resilience in human breast cancers;NAR Cancer;2023-06-09

3. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE);Breast Cancer Research;2023-01-11

4. BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer;Cancers;2022-05-24

5. PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer;npj Breast Cancer;2022-02-18